Midazolam (Nasal)

Introduction Overview

Generic Name

midazolam (nasal)

Brand Name

Nayzilam

Dosage Form

nasal spray

Drug Class

Benzodiazepines

Pharmacokinetics

Absorption: Midazolam administered via the intranasal route in the form of Nayzilam nasal spray demonstrates rapid and efficient absorption through the highly vascularized nasal mucosa. This delivery bypasses gastrointestinal absorption and first-pass hepatic metabolism, resulting in prompt onset of action, typically within 10 minutes. Peak plasma concentrations are generally attained rapidly, facilitating swift therapeutic effects critical in acute seizure management. The lipophilic nature of midazolam facilitates its absorption across the nasal epithelium. Clinical studies confirm high bioavailability of intranasal midazolam, comparable to intravenous administration, making this route preferable for rapid seizure control when intravenous access is not feasible. Factors such as nasal congestion, mucosal damage, or concurrent nasal conditions may influence absorption kinetics.

Distribution: Midazolam is extensively distributed throughout body tissues due to its high lipid solubility, with rapid cross of the blood-brain barrier ensuring effective central nervous system (CNS) sedation and anticonvulsant activity. It exhibits a volume of distribution averaging 1.5-3.7 L/kg. In plasma, midazolam is approximately 97% protein-bound, primarily to albumin, influencing its free active concentrations. The rapid onset is attributed to such effective CNS penetration. Midazolam distributes into adipose tissue, CNS, and muscle, with distribution phase half-life approximately 6-15 minutes, reflecting swift peripheral tissue uptake before elimination.

Metabolism: Midazolam is extensively metabolized by the hepatic cytochrome P450 enzyme system, predominantly CYP3A4 isoenzyme, to its primary active metabolite, 1-hydroxymidazolam, which possesses approximately 50% of the parent drug's pharmacologic activity. The biotransformation includes hydroxylation, which facilitates eventual renal elimination. Metabolism is subject to significant interpatient variability due to CYP3A4 activity variation, drug-drug interactions, and liver function status. Concomitant administration of CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics) can increase midazolam plasma levels, potentially leading to enhanced or prolonged effects.

Elimination: The elimination of midazolam and its metabolites occurs primarily through renal excretion after glucuronidation of the hydroxylated metabolites. The drug has a terminal elimination half-life ranging from 1.5 to 4 hours in healthy adults. Renal impairment can alter metabolite clearance but typically does not necessitate dosage adjustment. The drug’s clearance may be reduced in patients with hepatic impairment, necessitating cautious titration. Due to its rapid clearance, midazolam's sedative and anticonvulsant effects are relatively short-lived, necessitating potentially repeated dosing within clinical limits during seizure clusters.

Dosage Forms

Available Dosage Forms: Nayzilam is formulated exclusively as a nasal spray, designed for intranasal administration to deliver midazolam rapidly for acute seizure control. Each spray delivers a fixed dose of 5 mg of midazolam in a metered intranasal spray device.

Dosages for Adults and Adolescents: The recommended initial dose for both adults and pediatric patients aged 12 years and older is 5 mg administered as one spray in a single nostril. If seizures persist after 10 minutes, a second 5 mg dose (one spray) may be administered in the opposite nostril. The total maximum dose per day should not exceed 10 mg. Repeat dosing to treat seizure clusters more than once every three days is not recommended, with a maximum of five seizure cluster treatments in 30 days to prevent drug accumulation and dependence.

Specific Patient Populations: Safety and effectiveness have not been established in children under 12 years of age, thus usage in this population is not recommended. Dosage adjustments in elderly patients have not been definitively established; however, cautious use is advised due to increased sensitivity and altered pharmacokinetics. Patients with hepatic impairment should be monitored closely due to prolonged drug clearance. Intranasal administration is contraindicated in patients with nasal mucosa damage or conditions that may affect absorption. Use caution in patients with respiratory compromise, as midazolam may exacerbate respiratory depression.

Mechanism Of Action

Midazolam, the active ingredient in Nayzilam, is a short-acting benzodiazepine that exerts its therapeutic effects primarily by potentiating the activity of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system. At the molecular level, midazolam binds with high affinity to the benzodiazepine site on the GABA-A receptor complex. This binding enhances the receptor's affinity for GABA, resulting in increased opening frequency of chloride ion channels.

The increased chloride influx hyperpolarizes neuronal membranes, reducing neuronal excitability and preventing the propagation of seizure activity. This mechanism effectively depresses the CNS, producing sedative, anxiolytic, anticonvulsant, and muscle-relaxant effects. Midazolam's high lipid solubility facilitates rapid penetration across the blood-brain barrier, enabling prompt seizure suppression.

Cellular pathways modulated by midazolam include inhibitory synaptic transmission involving GABAergic interneurons, leading to decreased neuronal firing in epileptogenic brain regions. Unlike other anticonvulsants targeting ion channels or excitatory neurotransmitter receptors, midazolam’s mechanism is indirect, relying on enhancement of inhibitory neurotransmission which provides rapid seizure cluster termination.

Clinically, this mechanism underpins its utility in aborting acute repetitive seizures or seizure clusters that may not respond adequately to chronic anticonvulsants. Compared to other benzodiazepines like diazepam, midazolam offers faster onset and shorter duration via intranasal delivery, enhancing out-of-hospital seizure management. Extensive clinical trials and pharmacodynamic studies support midazolam’s efficacy and safety in this context.

Pharmacological Actions

Potentiation of GABAergic inhibitory neurotransmission via allosteric modulation of GABA-A receptors
Rapid CNS depressant effects including sedation, anxiolysis, muscle relaxation, and anticonvulsant properties
Short-acting benzodiazepine activity favorable for acute seizure cluster termination
Facilitation of chloride ion influx leading to neuronal membrane hyperpolarization and decreased excitability
Rapid absorption and onset from nasal mucosa, enabling timely seizure control without intravenous access
Metabolized to active 1-hydroxymidazolam, prolonging anticonvulsant effects while maintaining an acceptable safety profile
Reduction in the frequency and severity of seizure clusters in patients with epilepsy
Minimal accumulation with acute intermittent dosing due to efficient metabolism and elimination
CNS depressant action with potential to precipitate respiratory depression, particularly with concomitant CNS depressants
Potential to cause reversible anterograde amnesia in higher doses or prolonged use
Controlled substance (C-IV) with potential for misuse, dependence, and withdrawal symptoms upon abrupt cessation
Dose-dependent suppression of epileptiform activity in neuronal networks
Benzodiazepine receptor agonist properties with rapid onset and short half-life aiding outpatient seizure management
Demonstrated efficacy in aborting acute repetitive seizures in both adult and adolescent populations
Interaction with other CNS depressants can potentiate sedative and respiratory depressive effects

Therapeutic Or Clinical Uses

Acute treatment of intermittent, stereotypic episodes of frequent seizure activity known as seizure clusters or acute repetitive seizures
Rescue therapy for seizure clusters in patients aged 12 years and older with epilepsy
Intranasal administration facilitates rapid intervention when intravenous or rectal routes are not feasible or practical
Bridging therapy to reduce seizure severity pending longer-term anticonvulsant adjustment
Management of breakthrough seizures in patients on chronic anticonvulsant regimens
Alternative to intravenous benzodiazepines for emergency seizure control in ambulatory or home settings
Use as a short-term treatment option, limiting risks associated with chronic benzodiazepine therapy
Improvement in patient quality of life by reducing emergency department visits and hospitalization due to seizure clusters
Use in patients with predictable seizure recurrence patterns requiring intermittent rescue therapy
Facilitation of caregiver-administered seizure control via user-friendly nasal spray delivery
Reduction in seizure cluster duration and frequency when administered promptly after onset
Effective in both adult and adolescent populations aged 12 years and older
Emergency seizure management toolkit component in epilepsy care plans
Adjunctive therapy in epilepsy patients with refractory seizure clusters
Indicated under controlled prescription for safe and supervised use to mitigate risks of dependence

Side Or Adverse Effects

Drowsiness and sedation, potentially impairing alertness and psychomotor function
Respiratory depression, which may be severe especially if combined with opioids, alcohol, or other CNS depressants
Nasal discomfort including runny nose, irritation, or burning sensation in the nasal mucosa
Headache, occasionally reported, potentially related to drug administration or seizure activity
Paradoxical reactions such as agitation, irritability, aggressiveness, or excitation in some patients
Confusion or altered mental status, particularly in elderly or sensitive individuals
Visual disturbances such as blurred vision or ocular irritation
Potential for dependence and withdrawal syndrome upon abrupt discontinuation after prolonged use
Respiratory compromise requiring emergency intervention in severe overdose or susceptibility
Potential allergic reactions including rash, hives, or swelling of face and throat
Mood changes including depression, anxiety, or suicidal ideation, necessitating close monitoring
Memory impairment or anterograde amnesia with higher doses or frequent use
Paranoia or hallucinations in rare cases, particularly during withdrawal
Muscle weakness or loss of coordination, contributing to falls or injuries
Tolerance development with repeated dosing, requiring careful adherence to prescribed frequency limits

Precautions

Do not use in patients with narrow-angle glaucoma due to risk of exacerbation
Exercise caution in patients with respiratory disorders such as asthma, COPD, or chronic bronchitis
Assess hepatic and renal function prior to use; dose adjustments may be necessary in impairment
Avoid concomitant use with other CNS depressants unless supervised by a healthcare provider
Monitor for signs of respiratory depression especially in elderly or those with compromised pulmonary status
Advise patients to avoid alcohol and other sedating substances during therapy
Use appropriate counseling to prevent misuse, abuse, and diversion due to controlled substance status
Reinforce to caregivers signs of overdose or severe sedation requiring emergency care
Gradual tapering recommended to prevent withdrawal symptoms after long-term or repeated use
Evaluate mental health status due to risk of mood changes, depression, or suicidal ideation
Avoid use in children under 12 years, as safety and efficacy have not been established
Ensure proper storage to prevent accidental ingestion or misuse by others
Use with caution in patients with history of drug or alcohol dependence
Inform patients of possible impairment of ability to drive or operate machinery
Provide clear instructions on correct intranasal administration technique for maximal efficacy

Warnings

Risk of respiratory depression and possible apnea, especially with concurrent opioid or CNS depressants use
Potential for abuse, misuse, dependence, and addiction; Nayzilam is a Schedule IV controlled substance
Life-threatening withdrawal symptoms may occur if medication is discontinued abruptly after prolonged use
Not recommended to be used for more than one seizure cluster every three days or more than five per month
Contraindicated in patients with known hypersensitivity to midazolam or benzodiazepines
Use may cause profound sedation, impairment of mental and physical abilities requiring supervision
Risk of increased suicidal thoughts or behaviors; patients and caregivers should monitor for mood changes
Overdose can result in coma, respiratory arrest, or death if not managed promptly
Avoid use in patients with severe hepatic impairment without medical supervision
Safety and efficacy in children under 12 years have not been established; drug use in this group is avoided
Caregiver should seek emergency medical attention if patient develops difficult breathing or unresponsiveness
Nayzilam may exacerbate symptoms of depression or anxiety, and worsen psychiatric disorders
Abrupt cessation after long-term use may trigger status epilepticus or severe withdrawal seizures
Use with caution in patients with chronic respiratory insufficiency or heart failure
Ensure secure storage to prevent accidental ingestion or misuse especially in households with children or substance abuse history

Contraindication

Known hypersensitivity or allergy to midazolam or any benzodiazepine component
Patients with narrow-angle glaucoma due to increased intraocular pressure risk
Severe respiratory depression or pulmonary insufficiency without ventilatory support
Use with potent CYP3A4 inhibitors without appropriate adjustment, due to risk of toxicity
Patients experiencing acute alcohol intoxication or intoxication with other CNS depressants
Known history of paradoxical reactions to benzodiazepines such as agitation or aggression
Concomitant use with other sedatives contraindicated without close monitoring
Children younger than 12 years of age due to lack of safety and efficacy data
Patients with myasthenia gravis where muscle relaxant effects would be detrimental
Patients with severe hepatic impairment where metabolism is profoundly impaired
Patients with a history of substance use disorders not supervised under a controlled treatment plan
Cases of severe hypotension or shock where vasodilation by benzodiazepines would be harmful
Concomitant use with other prolonged CNS depressants in the absence of direct medical supervision
Pregnant women unless benefits outweigh risks; exposure may lead to neonatal withdrawal
Patients unable to protect airway without assisted ventilation

Drug Interactions

Additive CNS depressant effects when used with opioids, increasing risk of respiratory depression and sedation
CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin) increase midazolam plasma levels and prolong actions
CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce midazolam efficacy by enhancing metabolism
Alcohol consumption potentiates sedative and respiratory depressant effects, increasing overdose risk
Other benzodiazepines may cause cumulative sedation and respiratory depression if used concurrently
Certain antiepileptics adjusting hepatic enzyme activity may alter midazolam metabolism unpredictably
Muscle relaxants may potentiate neuromuscular blocking effects, leading to increased muscle weakness
Concomitant use with barbiturates enhances CNS depressant activity requiring dose adjustments
Drugs that prolong QT interval may have additive cardiac effects necessitating cautious monitoring
Use with monoamine oxidase inhibitors (MAOIs) is not recommended due to potential CNS synergism
Antidepressants such as SSRIs may alter midazolam metabolism through CYP450 interactions
Over-the-counter sedatives or herbal supplements like valerian or kava may augment sedation
Careful monitoring needed when combined with analgesics, antipsychotics, or anesthetics with CNS effects
Phenytoin and phenobarbital may modify midazolam clearance via enzyme induction
Concurrent use with HIV protease inhibitors can inhibit CYP3A4, increasing midazolam blood concentrations

Preparations Of The Drug

Nayzilam nasal spray delivering 5 mg midazolam per actuation for intranasal use
Each nasal spray device contains 2.5 mL solution, sufficient for five 5 mg sprays
Formulated as a clear, colorless, aqueous solution suitable for rapid intranasal absorption
Metered-dose spray device ensuring precise and reproducible 5 mg dosing per administration
Stored in blister pack to maintain sterility and protect from moisture until use
Supplied as a single-pack containing a nasal spray bottle with detailed patient instructions
Designed for short-term rescue use, not for chronic daily therapy
Prescribed with clear labeling regarding dosage limits and frequency restrictions
Packaging includes safety features to minimize accidental use or diversion
Accompanied by a patient medication guide explaining handling, administration, and storage
Supplied under controlled prescription regulations due to abuse potential
Formulation free from preservatives that could irritate nasal mucosa
Shelf life and storage recommendations specify room temperature, protected from heat and moisture
Non-oral formulation specifically designed to bypass gastrointestinal tract and hepatic first-pass effect
Can be integrated into home seizure emergency plans with caregiver instruction